Thats why we combed Reddit to find out what people are currently talking about in obesity and GLP-1 communities and asked the following medical experts to respond to readers most pressing questions: Kia Mitchell, MD Double board-certified family and obesity medicine physician and founder of the International Womens Obesity Network Marsha Novick, MD, FAAFP Spokesperson for The Obesity Society and board member of the American Board of Obesity Medicine Richele Corrado, DO, MPH Spokesperson for The Obesity Society and medical director, internist, and obesity medicine physician at Revolution Medicine, Health & Fitness Sherrie Singh-Bryan, PharmD, CDCES Clinical pharmacist and certified diabetic care and education specialist at Winn Army Community Hospital in Fort Stewart, Georgia Editors note: These interviews have been edited for length and clarity

This naturally occurring compound is present in virtually every cell of the human body, with the highest concentrations found in the liver, lungs, and heart
Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants
Real-world studies show that ongoing support leads to better, longer-lasting results real-world vs
Real-world effectiveness and safety of dapagliflozin therapy added to a GLP1 receptor agonist in patients with type 2 diabetes
Biomarker and Genetic Context: Why Personalization Matters Individual differences in oxidative stress, inflammatory markers, and genetic predispositions in metabolic pathways may influence how well GLP-1 therapy works and tolerability